PEOPLE - Restore Medical makes appointment:
This article was originally published in Clinica
Six-year-old US company Restore Medical (St Paul, Minnesota), which specialises in medical devices to correct sleep disorders, has appointed its first CFO. Christopher Geyen is a certified public accountant with over 12 years' experience in private and publicly traded medtech companies. His former posts include CFO for two other Minnesota firms, Urologix and, most recently, Acorn Cardiovascular. Restore Medical's proprietary Pillar Palatal Implant System is the first FDA-cleared treatment for snoring and mild-to-moderate obstructive sleep apnoea.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.